Key Points
In his view, it's only a hold now.
The pundit also reduced his price target by nearly half.
- 10 stocks we like better than Phreesia ›
Healthcare tech stock Phreesia (NYSE: PHR) could have used a pick-me-up on Wednesday. In a trading session that ended in positive territory, with the bellwether S&P 500 index gaining more than 1%, Phreesia's equity lost 3.5% of its value. Much of this was directly due to an analyst's recommendation downgrade.
Docked with a downgrade
The responsible party was Stan Berenshteyn of "Big Four" U.S. bank Wells Fargo. Early that morning, he changed his rating on Phreesia to equal weight (hold, in other words) from his preceding overweight (buy). Accompanying that was a significant price target modification, with Berenshteyn lowering his to $9 per share from $15.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
According to reports, the analyst made his move following channel checks on the healthcare tech company's offerings. He wrote that these indicated mounting competition, leading him to reduce his estimates for all-important subscription revenue.
Berenshteyn added that his research indicated patient intake software is more replaceable -- and thus subject to competing solutions -- than workflow software. This, in his view, makes Phreesia vulnerable.
Is the stock now underrated?
Another negative factor pointed out by the Wells Fargo prognosticator is the general profile of Phreesia's clients. He wrote that the company's strength is private practitioners, a segment being increasingly targeted by smaller developers, among other rivals.
While Berenshteyn makes some solid points in his update, I personally wouldn't be ready to throw in the towel on Phreesia.
Despite a recent cut to its annual revenue guidance that pushed the stock to historic lows, the company is becoming increasingly well-established in its business, and clients in the healthcare tech space often stick with the same vendor (thus avoiding disruptive shifts to new ones). I'm more bullish than the analyst; to me, its stock still looks like a buy.
Should you buy stock in Phreesia right now?
Before you buy stock in Phreesia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Phreesia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $481,750!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,352,457!*
Now, it’s worth noting Stock Advisor’s total average return is 990% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of May 20, 2026.
Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
